Plasma Albumin Levels Predict Risk for Nonsurvivors in Critically Ill Patients with Covid-19

Li, Juyi; Li, Meng; Zheng, Shasha; Li, Menglan; Zhang, Minghua; Sun, Minxian; Li, Xiang; Deng, Aiping; Cai, Yi; Zhang, Hongmei

doi:10.2217/bmm-2020-0254

Cited by 62 publications

(71 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Seventeen of these studies were from various COVID-19-designated hospitals in Wuhan City, which was the most infected area in China [2][3][4]8,[10][11][12][13][14][15][16][17][18][19][20][21] . There was also a nationwide multicenter study supported by the National Health Commission of China that enrolled 1099 patients from 552 hospitals in 30 provinces 6 .…”

Section: Epidemiology Of Covid-19-associated Acute Kidney Injurymentioning

confidence: 99%

Acute Kidney Injury in COVID-19: The Chinese Experience

Zheng

Zhao

2020

Seminars in Nephrology

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Epidemiology Of Covid-19-associated Acute Kidney Injurymentioning

confidence: 99%

Acute Kidney Injury in COVID-19: The Chinese Experience

Zheng

Zhao

2020

Seminars in Nephrology

View full text Add to dashboard Cite

show abstract

“…A case series by Liu et al demonstrated that increasing eosinophils may be an indicator of improvement in the COVID-19 disease [ 40 ]. It has also been noted that hypoalbuminemia is a predictor of mortality, independent of age and comorbidity burden [ 41 ]. Furthermore, a rise in neutrophil/lymphocyte count and neutrophil/platelet count may point towards a heightened risk of myocardial injury and mortality [ 42 ].…”

Section: Clinical Outcomesmentioning

confidence: 99%

COVID-19 and Hematology—What Do We Know So Far?

Khandait

Gandotra

Sachdeva

et al. 2020

SN Compr. Clin. Med.

View full text Add to dashboard Cite

The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), the causative agent of the novel coronavirus disease 2019 (COVID 19), was reported to the World Health Organization in late 2019. This disease quickly evolved into a public health concern and was declared a pandemic on March 11, 2020. COVID-19’s high transmission rate and potential to cause a spectrum of systemic diseases makes it imperative for researchers and clinicians worldwide to collaborate and develop a strategy to manage and contain this disease. Studies have shown a wide range of hematological abnormalities and virus-related coagulopathies in affected patients, resulting in an increased propensity to develop serious thrombotic complications or disseminated intravascular coagulation (DIC) in severe cases. The fatal implications of coagulopathy in the form of pulmonary embolism (PE), myocardial infarction (MI), and cerebral infarction compelled us to study in-depth the pathophysiology and treatment options related to COVID-19. This analysis reviews published reports on patients with confirmed SARS-COV-2 infection and associated coagulopathy, defined as abnormalities in the coagulation parameters prothrombin time (PT), activated partial thromboplastin time (aPTT), antithrombin time, fibrinogen, fibrin degradation products, and D-dimer. In this review, we present the hematological manifestations of COVID-19, focusing on virus-associated coagulopathy and relevant pathophysiology, clinical outcomes, and treatment.

show abstract

“…Age, comorbidities, c-reactive protein, albumin, cytokine, lactate dehydrogenase, D-dimer, albumin, platelet, lymphocyte, neutrophil, smoking, cough, expectoration, chest pain, dyspnea, CT manifestations, et al, have been reported to be associated with the severity of COVID-19 in some small studies in China, [15][16][17][18][19][20][21] and other countires. 13,22,23 Jiangsu, a province in China over 600 km from Hubei without common geographical borders and 80 million population, reported over 600 patients infected with COVID-19.…”

mentioning

confidence: 99%

Clinical characteristics and risk factors of patients with severe COVID-19 in Jiangsu province, China: a retrospective multicentre cohort study

Liu

Luo²,

Wang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Coronavirus Disease-2019 (COVID-19) has become a major health event that endangers people health throughout China and the world. Understanding the factors associated with COVID-19 disease severity could support the early identification of patients with high risk for disease progression, inform prevention and control activities, and potentially reduce mortality. This study aims to describe the characteristics of patients with COVID-19 and factors associated with severe or critically ill presentation.Methods: Multicentre retrospective cohort study of all individuals with confirmed Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infections diagnosed at 24 COVID-19-designated hospitals in Jiangsu province between the 10th January and 15th March 2020. Demographic, clinical, laboratory, and radiological data were collected at hospital admission and data on disease severity were collected at from admission. Patients were categorised as asymptomatic/mild/moderate, and severe/critically ill according to the worst level of COVID-19 recorded during hospitalisation.Results: A total of 625 patients, 64 (10.2%) were severe/critically ill and 561 (89.8%) were asymptomatic/mild/moderate. All patients were discharged and no patients died. Patients with severe/critically ill COVID-19 were more likely to be older, to be single onset (i.e. not to a cluster of cases in family/community), to have a medical history of hypertension and diabetes; had higher temperature, faster respiratory rates, lower peripheral capillary oxygen saturation (SpO2), and higher CT image quadrant scores and pulmonary opacity percentage; had increased C-reactive protein, fibrinogen, and D-dimer on admission; and had lower white blood cells, lymphocyte, and platelet counts and albumin on admission than asymptomatic/mild/moderate cases. Multivariable regression showed that odds of being a severe/critically ill case were associated with age (year) (OR 1.06, 95%CI 1.03-1.09), lymphocyte count (109/L) (OR 0.25, 95%CI 0.08-0.74), and pulmonary opacity in CT (per 5%) on admission (OR 1.31, 95%CI 1.15-1.51).Conclusions: Severe or critically ill patients with COVID-19 is about one-tenths of patients in Jiangsu. Age, lymphocyte count, and pulmonary opacity in CT on admission were associated with risk of severe or critically ill COVID-19.

show abstract

Plasma Albumin Levels Predict Risk for Nonsurvivors in Critically Ill Patients with Covid-19

Cited by 62 publications

References 25 publications

Acute Kidney Injury in COVID-19: The Chinese Experience

Acute Kidney Injury in COVID-19: The Chinese Experience

COVID-19 and Hematology—What Do We Know So Far?

Clinical characteristics and risk factors of patients with severe COVID-19 in Jiangsu province, China: a retrospective multicentre cohort study

Contact Info

Product

Resources

About